Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUVA vs Tofacitinib in Generalized Vitiligo
NCT07055529Phase 1Not yet recruiting
- Sponsor
- Hayatabad Medical Complex
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib oral solution in generalized vitiligo (2 arms), sponsored by Hayatabad Medical Complex. Primary endpoint: Vitiligo Area Scoring Index at 6 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
generalized vitiligo
Beyond the preview
Go deeper on NCT07055529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055529.